nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Bronchospasm—Zoledronate—osteoporosis	0.00366	0.00366	CcSEcCtD
Oritavancin—Infestation NOS—Pamidronate—osteoporosis	0.00364	0.00364	CcSEcCtD
Oritavancin—Infestation—Pamidronate—osteoporosis	0.00364	0.00364	CcSEcCtD
Oritavancin—Malnutrition—Ibandronate—osteoporosis	0.00363	0.00363	CcSEcCtD
Oritavancin—Dizziness—Calcium Acetate—osteoporosis	0.00359	0.00359	CcSEcCtD
Oritavancin—Infection—Etidronic acid—osteoporosis	0.00354	0.00354	CcSEcCtD
Oritavancin—Bronchospasm—Conjugated Estrogens—osteoporosis	0.00353	0.00353	CcSEcCtD
Oritavancin—Connective tissue disorder—Ethinyl Estradiol—osteoporosis	0.00346	0.00346	CcSEcCtD
Oritavancin—Angioedema—Estropipate—osteoporosis	0.00346	0.00346	CcSEcCtD
Oritavancin—Vomiting—Calcium Acetate—osteoporosis	0.00346	0.00346	CcSEcCtD
Oritavancin—Anaemia—Alendronate—osteoporosis	0.00344	0.00344	CcSEcCtD
Oritavancin—Angioedema—Alendronate—osteoporosis	0.0034	0.0034	CcSEcCtD
Oritavancin—Oedema peripheral—Risedronate—osteoporosis	0.00338	0.00338	CcSEcCtD
Oritavancin—Connective tissue disorder—Risedronate—osteoporosis	0.00337	0.00337	CcSEcCtD
Oritavancin—Anaemia—Ibandronate—osteoporosis	0.00335	0.00335	CcSEcCtD
Oritavancin—Erythema multiforme—Ethinyl Estradiol—osteoporosis	0.00333	0.00333	CcSEcCtD
Oritavancin—Infestation NOS—Zoledronate—osteoporosis	0.00332	0.00332	CcSEcCtD
Oritavancin—Infestation—Zoledronate—osteoporosis	0.00332	0.00332	CcSEcCtD
Oritavancin—Angioedema—Ibandronate—osteoporosis	0.00331	0.00331	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Etidronic acid—osteoporosis	0.00325	0.00325	CcSEcCtD
Oritavancin—Nausea—Calcium Acetate—osteoporosis	0.00323	0.00323	CcSEcCtD
Oritavancin—Myalgia—Estropipate—osteoporosis	0.00322	0.00322	CcSEcCtD
Oritavancin—Connective tissue disorder—Pamidronate—osteoporosis	0.00321	0.00321	CcSEcCtD
Oritavancin—Infestation NOS—Conjugated Estrogens—osteoporosis	0.0032	0.0032	CcSEcCtD
Oritavancin—Infestation—Conjugated Estrogens—osteoporosis	0.0032	0.0032	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.0032	0.0032	CcSEcCtD
Oritavancin—Cardiac disorder—Risedronate—osteoporosis	0.00319	0.00319	CcSEcCtD
Oritavancin—Immune system disorder—Ethinyl Estradiol—osteoporosis	0.00318	0.00318	CcSEcCtD
Oritavancin—Myalgia—Alendronate—osteoporosis	0.00317	0.00317	CcSEcCtD
Oritavancin—Myalgia—Raloxifene—osteoporosis	0.00312	0.00312	CcSEcCtD
Oritavancin—Immune system disorder—Risedronate—osteoporosis	0.0031	0.0031	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.0031	0.0031	CcSEcCtD
Oritavancin—Mediastinal disorder—Risedronate—osteoporosis	0.00309	0.00309	CcSEcCtD
Oritavancin—Myalgia—Ibandronate—osteoporosis	0.00309	0.00309	CcSEcCtD
Oritavancin—Infection—Estropipate—osteoporosis	0.00307	0.00307	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.00307	0.00307	CcSEcCtD
Oritavancin—Malnutrition—Ethinyl Estradiol—osteoporosis	0.00307	0.00307	CcSEcCtD
Oritavancin—Cardiac disorder—Pamidronate—osteoporosis	0.00303	0.00303	CcSEcCtD
Oritavancin—Nervous system disorder—Estropipate—osteoporosis	0.00303	0.00303	CcSEcCtD
Oritavancin—Myalgia—Calcitriol—osteoporosis	0.00302	0.00302	CcSEcCtD
Oritavancin—Infection—Alendronate—osteoporosis	0.00302	0.00302	CcSEcCtD
Oritavancin—Skin disorder—Estropipate—osteoporosis	0.003	0.003	CcSEcCtD
Oritavancin—Malnutrition—Risedronate—osteoporosis	0.00299	0.00299	CcSEcCtD
Oritavancin—Infection—Raloxifene—osteoporosis	0.00297	0.00297	CcSEcCtD
Oritavancin—Immune system disorder—Pamidronate—osteoporosis	0.00295	0.00295	CcSEcCtD
Oritavancin—Mediastinal disorder—Pamidronate—osteoporosis	0.00294	0.00294	CcSEcCtD
Oritavancin—Infection—Ibandronate—osteoporosis	0.00294	0.00294	CcSEcCtD
Oritavancin—Oedema peripheral—Zoledronate—osteoporosis	0.00294	0.00294	CcSEcCtD
Oritavancin—Nervous system disorder—Raloxifene—osteoporosis	0.00293	0.00293	CcSEcCtD
Oritavancin—Connective tissue disorder—Zoledronate—osteoporosis	0.00293	0.00293	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Estradiol—osteoporosis	0.00293	0.00293	CcSEcCtD
Oritavancin—Skin disorder—Raloxifene—osteoporosis	0.0029	0.0029	CcSEcCtD
Oritavancin—Nervous system disorder—Ibandronate—osteoporosis	0.0029	0.0029	CcSEcCtD
Oritavancin—Skin disorder—Ibandronate—osteoporosis	0.00287	0.00287	CcSEcCtD
Oritavancin—Nausea—Ergocalciferol—osteoporosis	0.00285	0.00285	CcSEcCtD
Oritavancin—Malnutrition—Pamidronate—osteoporosis	0.00284	0.00284	CcSEcCtD
Oritavancin—Urticaria—Etidronic acid—osteoporosis	0.00283	0.00283	CcSEcCtD
Oritavancin—Oedema peripheral—Conjugated Estrogens—osteoporosis	0.00283	0.00283	CcSEcCtD
Oritavancin—Bronchospasm—Estradiol—osteoporosis	0.00282	0.00282	CcSEcCtD
Oritavancin—Skin disorder—Calcitriol—osteoporosis	0.00281	0.00281	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Estropipate—osteoporosis	0.00281	0.00281	CcSEcCtD
Oritavancin—Angioedema—Ethinyl Estradiol—osteoporosis	0.0028	0.0028	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Alendronate—osteoporosis	0.00277	0.00277	CcSEcCtD
Oritavancin—Cardiac disorder—Zoledronate—osteoporosis	0.00277	0.00277	CcSEcCtD
Oritavancin—Anaemia—Risedronate—osteoporosis	0.00276	0.00276	CcSEcCtD
Oritavancin—Angioedema—Risedronate—osteoporosis	0.00273	0.00273	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Raloxifene—osteoporosis	0.00272	0.00272	CcSEcCtD
Oritavancin—Erythema multiforme—Conjugated Estrogens—osteoporosis	0.00271	0.00271	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Ibandronate—osteoporosis	0.0027	0.0027	CcSEcCtD
Oritavancin—Immune system disorder—Zoledronate—osteoporosis	0.00269	0.00269	CcSEcCtD
Oritavancin—Mediastinal disorder—Zoledronate—osteoporosis	0.00269	0.00269	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Estropipate—osteoporosis	0.00266	0.00266	CcSEcCtD
Oritavancin—Cardiac disorder—Conjugated Estrogens—osteoporosis	0.00266	0.00266	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Calcitriol—osteoporosis	0.00264	0.00264	CcSEcCtD
Oritavancin—Hypersensitivity—Etidronic acid—osteoporosis	0.00263	0.00263	CcSEcCtD
Oritavancin—Anaemia—Pamidronate—osteoporosis	0.00263	0.00263	CcSEcCtD
Oritavancin—Angioedema—Pamidronate—osteoporosis	0.0026	0.0026	CcSEcCtD
Oritavancin—Malnutrition—Zoledronate—osteoporosis	0.0026	0.0026	CcSEcCtD
Oritavancin—Immune system disorder—Conjugated Estrogens—osteoporosis	0.00259	0.00259	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.00259	0.00259	CcSEcCtD
Oritavancin—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.00259	0.00259	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Raloxifene—osteoporosis	0.00258	0.00258	CcSEcCtD
Oritavancin—Infestation NOS—Estradiol—osteoporosis	0.00256	0.00256	CcSEcCtD
Oritavancin—Infestation—Estradiol—osteoporosis	0.00256	0.00256	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00256	0.00256	CcSEcCtD
Oritavancin—Myalgia—Risedronate—osteoporosis	0.00254	0.00254	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.00253	0.00253	CcSEcCtD
Oritavancin—Pruritus—Etidronic acid—osteoporosis	0.00252	0.00252	CcSEcCtD
Oritavancin—Malnutrition—Conjugated Estrogens—osteoporosis	0.0025	0.0025	CcSEcCtD
Oritavancin—Infection—Ethinyl Estradiol—osteoporosis	0.00249	0.00249	CcSEcCtD
Oritavancin—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00245	0.00245	CcSEcCtD
Oritavancin—Urticaria—Estropipate—osteoporosis	0.00245	0.00245	CcSEcCtD
Oritavancin—Diarrhoea—Etidronic acid—osteoporosis	0.00244	0.00244	CcSEcCtD
Oritavancin—Skin disorder—Ethinyl Estradiol—osteoporosis	0.00243	0.00243	CcSEcCtD
Oritavancin—Infection—Risedronate—osteoporosis	0.00242	0.00242	CcSEcCtD
Oritavancin—Myalgia—Pamidronate—osteoporosis	0.00242	0.00242	CcSEcCtD
Oritavancin—Urticaria—Alendronate—osteoporosis	0.00241	0.00241	CcSEcCtD
Oritavancin—Anaemia—Zoledronate—osteoporosis	0.0024	0.0024	CcSEcCtD
Oritavancin—Nervous system disorder—Risedronate—osteoporosis	0.00239	0.00239	CcSEcCtD
Oritavancin—Angioedema—Zoledronate—osteoporosis	0.00237	0.00237	CcSEcCtD
Oritavancin—Skin disorder—Risedronate—osteoporosis	0.00237	0.00237	CcSEcCtD
Oritavancin—Urticaria—Ibandronate—osteoporosis	0.00235	0.00235	CcSEcCtD
Oritavancin—Infection—Pamidronate—osteoporosis	0.0023	0.0023	CcSEcCtD
Oritavancin—Urticaria—Calcitriol—osteoporosis	0.0023	0.0023	CcSEcCtD
Oritavancin—Angioedema—Conjugated Estrogens—osteoporosis	0.00228	0.00228	CcSEcCtD
Oritavancin—Hypersensitivity—Estropipate—osteoporosis	0.00227	0.00227	CcSEcCtD
Oritavancin—Nervous system disorder—Pamidronate—osteoporosis	0.00227	0.00227	CcSEcCtD
Oritavancin—Vomiting—Etidronic acid—osteoporosis	0.00227	0.00227	CcSEcCtD
Oritavancin—Oedema peripheral—Estradiol—osteoporosis	0.00226	0.00226	CcSEcCtD
Oritavancin—Tachycardia—Pamidronate—osteoporosis	0.00226	0.00226	CcSEcCtD
Oritavancin—Connective tissue disorder—Estradiol—osteoporosis	0.00226	0.00226	CcSEcCtD
Oritavancin—Rash—Etidronic acid—osteoporosis	0.00225	0.00225	CcSEcCtD
Oritavancin—Dermatitis—Etidronic acid—osteoporosis	0.00225	0.00225	CcSEcCtD
Oritavancin—Hypersensitivity—Alendronate—osteoporosis	0.00224	0.00224	CcSEcCtD
Oritavancin—Headache—Etidronic acid—osteoporosis	0.00223	0.00223	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Risedronate—osteoporosis	0.00222	0.00222	CcSEcCtD
Oritavancin—Myalgia—Zoledronate—osteoporosis	0.00221	0.00221	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00219	0.00219	CcSEcCtD
Oritavancin—Pruritus—Estropipate—osteoporosis	0.00218	0.00218	CcSEcCtD
Oritavancin—Hypersensitivity—Ibandronate—osteoporosis	0.00218	0.00218	CcSEcCtD
Oritavancin—Erythema multiforme—Estradiol—osteoporosis	0.00217	0.00217	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00216	0.00216	CcSEcCtD
Oritavancin—Pruritus—Alendronate—osteoporosis	0.00215	0.00215	CcSEcCtD
Oritavancin—Hypersensitivity—Calcitriol—osteoporosis	0.00213	0.00213	CcSEcCtD
Oritavancin—Cardiac disorder—Estradiol—osteoporosis	0.00213	0.00213	CcSEcCtD
Oritavancin—Myalgia—Conjugated Estrogens—osteoporosis	0.00213	0.00213	CcSEcCtD
Oritavancin—Nausea—Etidronic acid—osteoporosis	0.00212	0.00212	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00211	0.00211	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.00211	0.00211	CcSEcCtD
Oritavancin—Diarrhoea—Estropipate—osteoporosis	0.00211	0.00211	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Risedronate—osteoporosis	0.00211	0.00211	CcSEcCtD
Oritavancin—Infection—Zoledronate—osteoporosis	0.0021	0.0021	CcSEcCtD
Oritavancin—Pruritus—Ibandronate—osteoporosis	0.00209	0.00209	CcSEcCtD
Oritavancin—Diarrhoea—Alendronate—osteoporosis	0.00208	0.00208	CcSEcCtD
Oritavancin—Nervous system disorder—Zoledronate—osteoporosis	0.00208	0.00208	CcSEcCtD
Oritavancin—Immune system disorder—Estradiol—osteoporosis	0.00208	0.00208	CcSEcCtD
Oritavancin—Mediastinal disorder—Estradiol—osteoporosis	0.00207	0.00207	CcSEcCtD
Oritavancin—Tachycardia—Zoledronate—osteoporosis	0.00207	0.00207	CcSEcCtD
Oritavancin—Skin disorder—Zoledronate—osteoporosis	0.00206	0.00206	CcSEcCtD
Oritavancin—Pruritus—Calcitriol—osteoporosis	0.00205	0.00205	CcSEcCtD
Oritavancin—Diarrhoea—Raloxifene—osteoporosis	0.00205	0.00205	CcSEcCtD
Oritavancin—Dizziness—Estropipate—osteoporosis	0.00204	0.00204	CcSEcCtD
Oritavancin—Infection—Conjugated Estrogens—osteoporosis	0.00203	0.00203	CcSEcCtD
Oritavancin—Diarrhoea—Ibandronate—osteoporosis	0.00203	0.00203	CcSEcCtD
Oritavancin—Dizziness—Alendronate—osteoporosis	0.00201	0.00201	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Pamidronate—osteoporosis	0.002	0.002	CcSEcCtD
Oritavancin—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.002	0.002	CcSEcCtD
Oritavancin—Malnutrition—Estradiol—osteoporosis	0.002	0.002	CcSEcCtD
Oritavancin—Tachycardia—Conjugated Estrogens—osteoporosis	0.00199	0.00199	CcSEcCtD
Oritavancin—Urticaria—Ethinyl Estradiol—osteoporosis	0.00199	0.00199	CcSEcCtD
Oritavancin—Diarrhoea—Calcitriol—osteoporosis	0.00198	0.00198	CcSEcCtD
Oritavancin—Skin disorder—Conjugated Estrogens—osteoporosis	0.00198	0.00198	CcSEcCtD
Oritavancin—Dizziness—Raloxifene—osteoporosis	0.00198	0.00198	CcSEcCtD
Oritavancin—Vomiting—Estropipate—osteoporosis	0.00196	0.00196	CcSEcCtD
Oritavancin—Dizziness—Ibandronate—osteoporosis	0.00196	0.00196	CcSEcCtD
Oritavancin—Rash—Estropipate—osteoporosis	0.00195	0.00195	CcSEcCtD
Oritavancin—Dermatitis—Estropipate—osteoporosis	0.00194	0.00194	CcSEcCtD
Oritavancin—Urticaria—Risedronate—osteoporosis	0.00194	0.00194	CcSEcCtD
Oritavancin—Headache—Estropipate—osteoporosis	0.00193	0.00193	CcSEcCtD
Oritavancin—Vomiting—Alendronate—osteoporosis	0.00193	0.00193	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.00193	0.00193	CcSEcCtD
Oritavancin—Rash—Alendronate—osteoporosis	0.00192	0.00192	CcSEcCtD
Oritavancin—Dermatitis—Alendronate—osteoporosis	0.00191	0.00191	CcSEcCtD
Oritavancin—Headache—Alendronate—osteoporosis	0.0019	0.0019	CcSEcCtD
Oritavancin—Vomiting—Raloxifene—osteoporosis	0.0019	0.0019	CcSEcCtD
Oritavancin—Rash—Raloxifene—osteoporosis	0.00189	0.00189	CcSEcCtD
Oritavancin—Dermatitis—Raloxifene—osteoporosis	0.00188	0.00188	CcSEcCtD
Oritavancin—Vomiting—Ibandronate—osteoporosis	0.00188	0.00188	CcSEcCtD
Oritavancin—Headache—Raloxifene—osteoporosis	0.00187	0.00187	CcSEcCtD
Oritavancin—Rash—Ibandronate—osteoporosis	0.00187	0.00187	CcSEcCtD
Oritavancin—Dermatitis—Ibandronate—osteoporosis	0.00186	0.00186	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.00186	0.00186	CcSEcCtD
Oritavancin—Headache—Ibandronate—osteoporosis	0.00185	0.00185	CcSEcCtD
Oritavancin—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00184	0.00184	CcSEcCtD
Oritavancin—Vomiting—Calcitriol—osteoporosis	0.00184	0.00184	CcSEcCtD
Oritavancin—Nausea—Estropipate—osteoporosis	0.00183	0.00183	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00183	0.00183	CcSEcCtD
Oritavancin—Angioedema—Estradiol—osteoporosis	0.00183	0.00183	CcSEcCtD
Oritavancin—Rash—Calcitriol—osteoporosis	0.00183	0.00183	CcSEcCtD
Oritavancin—Dermatitis—Calcitriol—osteoporosis	0.00183	0.00183	CcSEcCtD
Oritavancin—Headache—Calcitriol—osteoporosis	0.00182	0.00182	CcSEcCtD
Oritavancin—Nausea—Alendronate—osteoporosis	0.00181	0.00181	CcSEcCtD
Oritavancin—Hypersensitivity—Risedronate—osteoporosis	0.0018	0.0018	CcSEcCtD
Oritavancin—Nausea—Raloxifene—osteoporosis	0.00178	0.00178	CcSEcCtD
Oritavancin—Pruritus—Ethinyl Estradiol—osteoporosis	0.00177	0.00177	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.00176	0.00176	CcSEcCtD
Oritavancin—Nausea—Ibandronate—osteoporosis	0.00176	0.00176	CcSEcCtD
Oritavancin—Pruritus—Risedronate—osteoporosis	0.00173	0.00173	CcSEcCtD
Oritavancin—Nausea—Calcitriol—osteoporosis	0.00172	0.00172	CcSEcCtD
Oritavancin—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.00171	0.00171	CcSEcCtD
Oritavancin—Hypersensitivity—Pamidronate—osteoporosis	0.00171	0.00171	CcSEcCtD
Oritavancin—Myalgia—Estradiol—osteoporosis	0.0017	0.0017	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.00169	0.00169	CcSEcCtD
Oritavancin—Urticaria—Zoledronate—osteoporosis	0.00168	0.00168	CcSEcCtD
Oritavancin—Diarrhoea—Risedronate—osteoporosis	0.00167	0.00167	CcSEcCtD
Oritavancin—Dizziness—Ethinyl Estradiol—osteoporosis	0.00165	0.00165	CcSEcCtD
Oritavancin—Pruritus—Pamidronate—osteoporosis	0.00164	0.00164	CcSEcCtD
Oritavancin—Infection—Estradiol—osteoporosis	0.00162	0.00162	CcSEcCtD
Oritavancin—Urticaria—Conjugated Estrogens—osteoporosis	0.00162	0.00162	CcSEcCtD
Oritavancin—Dizziness—Risedronate—osteoporosis	0.00161	0.00161	CcSEcCtD
Oritavancin—Nervous system disorder—Estradiol—osteoporosis	0.0016	0.0016	CcSEcCtD
Oritavancin—Tachycardia—Estradiol—osteoporosis	0.00159	0.00159	CcSEcCtD
Oritavancin—Vomiting—Ethinyl Estradiol—osteoporosis	0.00159	0.00159	CcSEcCtD
Oritavancin—Diarrhoea—Pamidronate—osteoporosis	0.00159	0.00159	CcSEcCtD
Oritavancin—Skin disorder—Estradiol—osteoporosis	0.00159	0.00159	CcSEcCtD
Oritavancin—Rash—Ethinyl Estradiol—osteoporosis	0.00158	0.00158	CcSEcCtD
Oritavancin—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00158	0.00158	CcSEcCtD
Oritavancin—Headache—Ethinyl Estradiol—osteoporosis	0.00157	0.00157	CcSEcCtD
Oritavancin—Hypersensitivity—Zoledronate—osteoporosis	0.00156	0.00156	CcSEcCtD
Oritavancin—Vomiting—Risedronate—osteoporosis	0.00155	0.00155	CcSEcCtD
Oritavancin—Rash—Risedronate—osteoporosis	0.00154	0.00154	CcSEcCtD
Oritavancin—Dermatitis—Risedronate—osteoporosis	0.00154	0.00154	CcSEcCtD
Oritavancin—Dizziness—Pamidronate—osteoporosis	0.00153	0.00153	CcSEcCtD
Oritavancin—Headache—Risedronate—osteoporosis	0.00153	0.00153	CcSEcCtD
Oritavancin—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.0015	0.0015	CcSEcCtD
Oritavancin—Pruritus—Zoledronate—osteoporosis	0.0015	0.0015	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Estradiol—osteoporosis	0.00149	0.00149	CcSEcCtD
Oritavancin—Nausea—Ethinyl Estradiol—osteoporosis	0.00149	0.00149	CcSEcCtD
Oritavancin—Vomiting—Pamidronate—osteoporosis	0.00147	0.00147	CcSEcCtD
Oritavancin—Rash—Pamidronate—osteoporosis	0.00146	0.00146	CcSEcCtD
Oritavancin—Dermatitis—Pamidronate—osteoporosis	0.00146	0.00146	CcSEcCtD
Oritavancin—Headache—Pamidronate—osteoporosis	0.00145	0.00145	CcSEcCtD
Oritavancin—Diarrhoea—Zoledronate—osteoporosis	0.00145	0.00145	CcSEcCtD
Oritavancin—Nausea—Risedronate—osteoporosis	0.00145	0.00145	CcSEcCtD
Oritavancin—Pruritus—Conjugated Estrogens—osteoporosis	0.00144	0.00144	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Estradiol—osteoporosis	0.00141	0.00141	CcSEcCtD
Oritavancin—Dizziness—Zoledronate—osteoporosis	0.0014	0.0014	CcSEcCtD
Oritavancin—Diarrhoea—Conjugated Estrogens—osteoporosis	0.0014	0.0014	CcSEcCtD
Oritavancin—Nausea—Pamidronate—osteoporosis	0.00138	0.00138	CcSEcCtD
Oritavancin—Dizziness—Conjugated Estrogens—osteoporosis	0.00135	0.00135	CcSEcCtD
Oritavancin—Vomiting—Zoledronate—osteoporosis	0.00135	0.00135	CcSEcCtD
Oritavancin—Rash—Zoledronate—osteoporosis	0.00134	0.00134	CcSEcCtD
Oritavancin—Dermatitis—Zoledronate—osteoporosis	0.00133	0.00133	CcSEcCtD
Oritavancin—Headache—Zoledronate—osteoporosis	0.00133	0.00133	CcSEcCtD
Oritavancin—Vomiting—Conjugated Estrogens—osteoporosis	0.0013	0.0013	CcSEcCtD
Oritavancin—Urticaria—Estradiol—osteoporosis	0.0013	0.0013	CcSEcCtD
Oritavancin—Rash—Conjugated Estrogens—osteoporosis	0.00129	0.00129	CcSEcCtD
Oritavancin—Dermatitis—Conjugated Estrogens—osteoporosis	0.00128	0.00128	CcSEcCtD
Oritavancin—Headache—Conjugated Estrogens—osteoporosis	0.00128	0.00128	CcSEcCtD
Oritavancin—Nausea—Zoledronate—osteoporosis	0.00126	0.00126	CcSEcCtD
Oritavancin—Nausea—Conjugated Estrogens—osteoporosis	0.00121	0.00121	CcSEcCtD
Oritavancin—Hypersensitivity—Estradiol—osteoporosis	0.0012	0.0012	CcSEcCtD
Oritavancin—Pruritus—Estradiol—osteoporosis	0.00115	0.00115	CcSEcCtD
Oritavancin—Diarrhoea—Estradiol—osteoporosis	0.00112	0.00112	CcSEcCtD
Oritavancin—Dizziness—Estradiol—osteoporosis	0.00108	0.00108	CcSEcCtD
Oritavancin—Vomiting—Estradiol—osteoporosis	0.00104	0.00104	CcSEcCtD
Oritavancin—Rash—Estradiol—osteoporosis	0.00103	0.00103	CcSEcCtD
Oritavancin—Dermatitis—Estradiol—osteoporosis	0.00103	0.00103	CcSEcCtD
Oritavancin—Headache—Estradiol—osteoporosis	0.00102	0.00102	CcSEcCtD
Oritavancin—Nausea—Estradiol—osteoporosis	0.00097	0.00097	CcSEcCtD
